SWK Holdings Co. (NASDAQ:SWKH) Shares Purchased by Barclays PLC

Barclays PLC increased its position in shares of SWK Holdings Co. (NASDAQ:SWKH) by 185.0% in the 3rd quarter, Holdings Channel reports. The firm owned 4,461 shares of the company’s stock after purchasing an additional 2,896 shares during the period. Barclays PLC’s holdings in SWK were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. SkyView Investment Advisors LLC grew its position in shares of SWK by 7.7% in the second quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock valued at $529,000 after purchasing an additional 2,234 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of SWK in the 2nd quarter valued at approximately $172,000. Dimensional Fund Advisors LP grew its stake in shares of SWK by 85.7% in the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock valued at $511,000 after buying an additional 13,892 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in shares of SWK in the third quarter valued at approximately $589,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

SWK Stock Performance

Shares of SWK stock opened at $16.12 on Friday. SWK Holdings Co. has a one year low of $15.14 and a one year high of $18.49. The business has a 50-day simple moving average of $16.16 and a 200-day simple moving average of $16.71. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.06 and a current ratio of 5.06. The company has a market cap of $197.20 million, a PE ratio of 17.33 and a beta of 0.36.

SWK Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.